Benjamin Solomon

Alıntı yapanlar

	Hepsi	2020 yılından bugüne
Alıntılar	62132	30470
h-endeksi	91	73
i10-endeksi	276	216

7000

3500

1750

5250

2010201120122013201420152016201720182019202020212022202320242025245 750 1624 2356 3146 4185 4849 4595 4148 4350 5002 6051 5840 5805 6553 1006

Genel erişim

Tümünü görüntüle

90 makale

13 makale

genel erişime açık olanlar

genel erişime açık olmayanlar

Finansman sağlayan kuruluşun getirdiği zorunluluğa dayalı olarak

Katkıda bulunan yazarlar

Ross Camidgecuanschutz.edu üzerinde doğrulanmış e-posta adresine sahip
Dong-Wan KimSeoul National University Hospitalsnu.ac.kr üzerinde doğrulanmış e-posta adresine sahip
Yi-long WuProfessor of Oncology, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospitalgdph.org.cn üzerinde doğrulanmış e-posta adresine sahip
Sai-Hong Ignatius OuUniversity of California Irvineuci.edu üzerinde doğrulanmış e-posta adresine sahip
Gregory J. Riely, MD, PhDMemorial Sloan Kettering Cancer CenterMSKCC.org üzerinde doğrulanmış e-posta adresine sahip
Danny RischinPeter MacCallum Cancer Centrepetermac.org üzerinde doğrulanmış e-posta adresine sahip
Daniel SW TanNational Cancer Centre Singaporenccs.com.sg üzerinde doğrulanmış e-posta adresine sahip
Stephen FoxMelbournepetermac.org üzerinde doğrulanmış e-posta adresine sahip
F BlackhallUniversity of Manchesterchristie.nhs.uk üzerinde doğrulanmış e-posta adresine sahip
Richard J YoungPeter MacCallum Cancer centerpetermac.org üzerinde doğrulanmış e-posta adresine sahip
David BallPeter macCallum cancer centrepetermac.org üzerinde doğrulanmış e-posta adresine sahip
geoffrey liuPrincess Margaret Cancer Centre / University of Torontouhn.on.ca üzerinde doğrulanmış e-posta adresine sahip
Alexander DrilonMemorial Sloan Kettering Cancer Centermskcc.org üzerinde doğrulanmış e-posta adresine sahip
Grant McArthurPeter MacCallum Cancer Centrepetermac.org üzerinde doğrulanmış e-posta adresine sahip
Daniel Botelho CostaProfessor of Medicine | Harvard Medical School | Beth Israel Deaconess Medical Centerbidmc.harvard.edu üzerinde doğrulanmış e-posta adresine sahip
kenneth o'byrneQueensland University of Technology; Princess Alexandra Hospital; Translational Research Institutequt.edu.au üzerinde doğrulanmış e-posta adresine sahip
Ravi SalgiaCity of Hopecoh.org üzerinde doğrulanmış e-posta adresine sahip
julien mazieresCHU TOULOUSE, INSERM UMR1037, Université Paul Sabatierchu-toulouse.fr üzerinde doğrulanmış e-posta adresine sahip
Federico CappuzzoIstituto Nazionale Tumori Regina Elena, Roma, Italyifo.gov.it üzerinde doğrulanmış e-posta adresine sahip
Yung-Jue BangProfessorboconsulting.io üzerinde doğrulanmış e-posta adresine sahip

Takip et

Benjamin Solomon

Medical Oncologist, Peter MacCallum Cancer Centre

petermac.org üzerinde doğrulanmış e-posta adresine sahip

Medical Oncology Lung Cancer Phase I clinical trials


Başlık Alıntılara göre sırala Yıla göre sırala Başlığa göre sırala	Alıntı yapanlar Alıntı yapanlar	Yıl
Anaplastic lymphoma kinase inhibition in non–small-cell lung cancer EL Kwak, YJ Bang, DR Camidge, AT Shaw, B Solomon, RG Maki, SHI Ou, ... New England Journal of Medicine 363 (18), 1693-1703, 2010	5527	2010
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer AT Shaw, DW Kim, K Nakagawa, T Seto, L Crinó, MJ Ahn, T De Pas, ... New England Journal of Medicine 368 (25), 2385-2394, 2013	4157	2013
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer BJ Solomon, T Mok, DW Kim, YL Wu, K Nakagawa, T Mekhail, E Felip, ... New England Journal of Medicine 371 (23), 2167-2177, 2014	3733	2014
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK AT Shaw, BY Yeap, M Mino-Kenudson, SR Digumarthy, DB Costa, ... Journal of clinical oncology 27 (26), 4247-4253, 2009	2486	2009
Crizotinib in ROS1-rearranged non–small-cell lung cancer AT Shaw, SHI Ou, YJ Bang, DR Camidge, BJ Solomon, R Salgia, GJ Riely, ... New England Journal of Medicine 371 (21), 1963-1971, 2014	2256	2014
Comprehensive genomic profiles of small cell lung cancer J George, JS Lim, SJ Jang, Y Cun, L Ozretić, G Kong, F Leenders, X Lu, ... Nature 524 (7563), 47-53, 2015	2233	2015
Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer AT Shaw, DW Kim, R Mehra, DSW Tan, E Felip, LQM Chow, DR Camidge, ... New England Journal of Medicine 370 (13), 1189-1197, 2014	1876	2014
Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American … NI Lindeman, PT Cagle, DL Aisner, ME Arcila, MB Beasley, EH Bernicker, ... Archives of pathology & laboratory medicine 142 (3), 321-346, 2018	1645	2018
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study DR Camidge, YJ Bang, EL Kwak, AJ Iafrate, M Varella-Garcia, SB Fox, ... The lancet oncology 13 (10), 1011-1019, 2012	1568	2012
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer M Peifer, L Fernández-Cuesta, ML Sos, J George, D Seidel, LH Kasper, ... Nature genetics 44 (10), 1104-1110, 2012	1557	2012
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers R Katayama, AT Shaw, TM Khan, M Mino-Kenudson, BJ Solomon, ... Science translational medicine 4 (120), 120ra17-120ra17, 2012	1506	2012
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry J Mazieres, A Drilon, A Lusque, L Mhanna, AB Cortot, L Mezquita, ... Annals of Oncology 30 (8), 1321-1328, 2019	1219	2019
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis AT Shaw, BY Yeap, BJ Solomon, GJ Riely, J Gainor, JA Engelman, ... The lancet oncology 12 (11), 1004-1012, 2011	1155	2011
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer J Weiss, ML Sos, D Seidel, M Peifer, T Zander, JM Heuckmann, RT Ullrich, ... Science translational medicine 2 (62), 62ra93-62ra93, 2010	1024	2010
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer AT Shaw, TM Bauer, F de Marinis, E Felip, Y Goto, G Liu, J Mazieres, ... New England Journal of Medicine 383 (21), 2018-2029, 2020	941	2020
Prognostic Significance of p16^INK4A and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial D Rischin, RJ Young, R Fisher, SB Fox, QT Le, LJ Peters, B Solomon, ... Journal of clinical oncology 28 (27), 4142-4148, 2010	901	2010
Rociletinib in EGFR-mutated non–small-cell lung cancer LV Sequist, JC Soria, JW Goldman, HA Wakelee, SM Gadgeel, A Varga, ... New England Journal of Medicine 372 (18), 1700-1709, 2015	844	2015
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study BJ Solomon, B Besse, TM Bauer, E Felip, RA Soo, DR Camidge, R Chiari, ... The Lancet Oncology 19 (12), 1654-1667, 2018	820	2018
Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology … S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ... Advances in anatomic pathology 24 (6), 311-335, 2017	800	2017
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer A Drilon, GR Oxnard, DSW Tan, HHF Loong, M Johnson, J Gainor, ... New England Journal of Medicine 383 (9), 813-824, 2020	789	2020

Sistem, işlemi şu anda gerçekleştiremiyor. Daha sonra yeniden deneyin.

Makaleler 1–20

Yıllık alıntı sayısı

Mükerrer alıntılar

Birleştirilmiş alıntılar

Katkıda bulunan yazar ekleKatkıda bulunan yazarlar

Takip et

Alıntı yapanlar

Katkıda bulunan yazarlar